Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors ...
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...
5d
GlobalData on MSNAllurion’s weight loss balloon back on French marketAllurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...
Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...
Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss Allurion Technologies, Inc. (“Allurion” or the “Company ...
Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...
James Headen Pfitzer, Senior Director, Global Policy, Corporate Affairs, Viatris and Melissa Mitchell, AMR IA Secretariat LeadOur world is rapidly changing, and policymakers face no ...
Gate Neurosciences today announced it has entered a definitive agreement to acquire Boost Neuroscience and its leading proprietary platform for human synapse network analysis and synapse-targeted drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results